The designation of the imog036 Yamanaka line as a "best" candidate in research history stems from its role in resolving the ethical deadlock that plagued stem cell research in the early 2000s. Prior to iPSCs, the primary source of pluripotent cells was human embryos, leading to significant political and religious controversy.
While the iPS-TKB05 line (imog036) was a mouse line, its success paved the way for human applications. It validated the OSKM formula, which was swiftly applied to human cells in 2007. Today, the legacy of the "Yamanaka 1" lines is visible in clinical trials treating age-related macular degeneration, Parkinson’s disease, and heart failure. imog036 yamanaka 1 best